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Abstract
Background: Trials failed to demonstrate additional value of completion axillary lymph node dissection in case of
limited sentinel lymph node metastases in breast cancer patients undergoing breast conserving therapy. It has
been suggested that the low regional recurrence rates in these trials might partially be ascribed to accidental
irradiation of part of the axilla by whole breast radiation therapy, which precludes extrapolation of results to
mastectomy patients. The aim of the randomized controlled BOOG 2013–07 trial is therefore to investigate whether
completion axillary treatment can be safely omitted in sentinel lymph node positive breast cancer patients treated
with mastectomy.
Design: This study is designed as a non-inferiority randomized controlled multicentre trial. Women aged 18 years
or older diagnosed with unilateral invasive clinically T1-2 N0 breast cancer who are treated with mastectomy, and
who have a maximum of three axillary sentinel lymph nodes containing micro- and/or macrometastases, will be
randomized for completion axillary treatment versus no completion axillary treatment. Completion axillary
treatment can consist of completion axillary lymph node dissection or axillary radiation therapy. Primary endpoint is
regional recurrence rate at 5 years. Based on a 5-year regional recurrence free survival rate of 98 % among controls
and 96 % for study subjects, the sample size amounts 439 per arm (including 10 % lost to follow-up), to be able to
reject the null hypothesis that the rate for study and control subjects is inferior by at least 5 % with a probability of
0.8. Results will be reported after 5 and 10 years of follow-up.
Discussion: We hypothesize that completion axillary treatment can be safely omitted in sentinel node positive
breast cancer patients undergoing mastectomy. If confirmed, this study will significantly decrease the number of
breast cancer patients receiving extensive treatment of the axilla, thereby diminishing the risk of morbidity and
improving quality of life, while maintaining excellent regional control and without affecting survival.
Trial registration: The BOOG 2013–07 study is registered in the register of ClinicalTrials.gov since April 10, 2014,
Identifier: NCT02112682.
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Background
For a long time the standard procedure to assess the
axillary lymph node status in breast cancer was an
axillary lymph node dissection (ALND). This operation
is associated with significant morbidity and a decrease
in quality of life [1, 2]. The therapeutic benefit of this
operation – improving overall survival and maintaining
regional control – has been questioned in several trials.
The NSABP B-04 trial was initiated in 1971 and ran-
domized clinically node negative breast cancer patients
to radical mastectomy, mastectomy followed by axillary
radiation therapy, or mastectomy followed by a delayed
ALND after the development of palpable lymphadenopathy
during follow-up [3]. The ALND specimen of patients in
the radical mastectomy group contained lymph node
metastases in 40 % of the patients. Nevertheless, this trial
demonstrated that omitting primary axillary treatment of
occult positive lymph nodes in patients with a clinically
node negative status did not affect distant disease free- and
overall survival, even after 25 years of follow-up and
without the use of adjuvant systemic or radiation therapy.
A delayed ALND was performed in 18.6 % of the patients
in the mastectomy-only group, which is less than half of
the patients with occult positive lymph nodes based on the
radical mastectomy group [3]. The ‘wait-and-see’ policy
therefore prevented axillary overtreatment in the ma-
jority of patients. Despite these favourable results,
ALND remained to be the standard procedure to
assess the axillary lymph node status, partly due to ad-
juvant systemic therapy that appeared to be mainly
beneficial for node-positive breast cancer patients.
In the past 15 years, the sentinel lymph node biopsy
(SLNB) has become the standard, less invasive technique
for nodal staging of clinically node negative breast cancer
patients [4]. A completion ALND was, until recently,
routinely performed in patients with a metastasis in the
sentinel lymph node (SLN) [5].
The AMAROS trial demonstrated that axillary and peri-
clavicular radiation therapy could safely replace comple-
tion ALND in patients with clinically T1-2 breast cancer,
no palpable lymphadenopathy and a positive SLN, without
compromising the 5-year regional recurrence rate, disease
free- and overall survival [6]. Patients in the AMAROS
trial were treated with breast conserving therapy in 82 %,
with mastectomy in 18 %, and adjuvant systemic therapy
in 90 % of the cases. At five years, a significant lower
lymphedema rate based on arm circumference measure-
ments was observed, favouring the radiation therapy group.
Two recent trials further suggest that completion ALND
might be safely omitted [7, 8]. The ACOSOG Z0011 trial
randomized patients with clinically T1-2 breast cancer,
no palpable lymphadenopathy and 1–2 macrometa-
static SLNs, who were treated with breast conserving
therapy, to completion ALND or watchful waiting [7].
The ALND specimen of 27 % of the patients in the com-
pletion ALND group contained additional lymph node
metastases beyond the SLN, but omitting the completion
ALND in the watchful waiting arm did not result in an
inferior regional recurrence rate, disease free- or overall
survival [7, 9]. Findings of the ACOSOG Z0011 are sup-
ported by results of the IBCSG 23–01 trial, which revealed
that further axillary treatment can be safely omitted after
the detection of a micrometastasis in the SLN [8]. All
patients in the IBCSG 23–01 trial had a clinically T1-2
status and no palpable lymphadenopathy, 91 % was treated
with breast conserving therapy, 9 % with mastectomy and
97 % with adjuvant systemic therapy.
The clinically node negative patients in the AMAROS,
ACOSOG Z0011 and IBCSG 23–01 trial were selected by
physical examination of the axilla. In the Netherlands, an
axillary ultrasound next to physical examination is routinely
performed for preoperative lymph node staging, combined
with tissue sampling in case of a suspicious lymph node [5].
The ESMO breast cancer guideline also describes that an
ultrasound of the regional lymph nodes should be included
in the diagnostic work-up of breast cancer patients, and
recommends not to perform an SLNB when axillary lymph
node involvement is proven on ultrasound-guided biopsy
[10]. The accuracy of physical examination of the axilla for
preoperative lymph node staging is low, with a sensitivity of
up to 32 % for detecting axillary metastases [11, 12]. The
sensitivity of axillary ultrasound combined with tissue sam-
pling if indicated is 50–55 % [13, 14]. Furthermore, patients
with a more favourable tumour load are selected when an
axillary ultrasound is performed, as the total number of
nodal metastases is significantly lower after a negative axil-
lary ultrasound than after negative physical examination
[15]. In addition, a negative axillary ultrasound accurately
excludes advanced nodal disease (≥4 lymph node metasta-
ses) with a negative predictive value of 93–96 % [16, 17].
The performance of an axillary ultrasound for preopera-
tive nodal staging might therefore be beneficial when in-
corporating the omission of completion axillary treatment
in patients with SLN metastases into daily practice [18].
The AMAROS, ACOSOG Z0011 and IBCSG 23–01
trial were underpowered, as events occurred less common
than anticipated [6–8]. Low regional recurrence rates in
the study arms of these trials of 1.0 %, 0.9 % and 1.1 %,
respectively, might be due to treatment of most patients
with breast conserving therapy and adjuvant systemic
therapy. Whole breast radiation therapy in the context of
breast conserving therapy is known to decrease the regional
recurrence rate, most likely caused by accidental irradiation
of part of the axilla [19–21]. However, biology and sys-
temic therapy also play a role in achieving low regional
recurrence rates. The NSABP B-04 trial demonstrated
that less than half of the patients with occult nodal metasta-
ses develop clinically detectable lymph nodes, while none
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of the patients received adjuvant systemic therapy [3].
Reported pathologic complete response rates for axillary
lymph node metastases following primary systemic therapy
of up to 40 %, demonstrate that systemic therapy can eradi-
cate lymph node metastases [22, 23].
The non-inferior regional recurrence-, disease free- and
overall survival rates in the ACOSOG Z0011 and IBCSG
23–01 trial imply that extensive surgical treatment of lymph
node metastases with a completion ALND is not of added
value for breast cancer patients with a clinically T1-2 status,
no palpable lymphadenopathy, limited SLN metastases,
who are treated with breast conserving therapy and adju-
vant systemic therapy [7, 8]. Results of the ACOSOG
Z0011 and IBCSG 23–01 trial cannot be extrapolated
to SLN positive patients treated with mastectomy, as
these patients do not routinely receive adjuvant radi-
ation therapy.
Therefore, we propose the randomized controlled BOOG
2013–07 trial to prove that completion axillary treatment
can be safely omitted in breast cancer patients with a clin-
ically T1-2 status, a negative axillary ultrasound and limited
SLN metastases, who are treated with a mastectomy. We
aim to decrease the number of breast cancer patients re-
ceiving overtreatment of the axilla, to diminish the risk of
morbidity and to improve quality of life, while maintaining
excellent regional control and without affecting survival.
Main study objectives
The main aim of the BOOG 2013–07 study is to investigate
whether omitting completion axillary treatment is non-
inferior to completion axillary treatment in terms of the 5
and 10-year regional recurrence rate, in breast cancer pa-
tients with a clinically T1-2 status, a negative axillary ultra-
sound and limited SLN metastases, who are treated with a
mastectomy. Secondary objectives that are assessed during
a follow-up of 10 years include the assessment of quality of
life, distant-disease free survival, overall survival, local re-
currence rate, contralateral breast cancer, administration of
adjuvant radiation therapy, and delayed axillary treatment.
Methods
Study design
The BOOG 2013–07 is a Dutch non-inferiority randomized
controlled multicentre trial. Patients with clinically T1-2
invasive breast cancer, negative axillary ultrasound and lim-
ited SLN metastases, who are treated with mastectomy, are
randomized to completion axillary treatment or no comple-
tion axillary treatment. Outcome will be evaluated after 5
and 10 years of follow-up. This study will be performed in
43 centres in the Netherlands. The study was conducted in
accordance to the standards of Good Clinical Practice, in
agreement with the Declaration of Helsinki and with
Dutch law in general and with the Medical Research
Involving Human Subjects Act (in Dutch: Wet Medisch-
wetenschappelijk Onderzoek met mensen) in particular.
This study was approved by the medical ethics commit-
tee of the Netherlands Cancer Institute - Antoni van
Leeuwenhoek Hospital (PTC14.0032/M14CAT). The
Board of Directors approved initiation of the study in
current participating centres that are open for accrual
(Additional file 1). The BOOG 2013–07 trial is registered
at ClinicalTrials.gov (NCT02112682).
Study population
Women aged 18 years or older diagnosed with clinically
T1-2 N0 invasive breast cancer, who are treated with a
mastectomy and who have a minimum of one micrometa-
static and a maximum of three macrometastatic axillary
SLNs, are eligible for inclusion. Clinically N0 is defined as
no signs of axillary lymph node metastases at physical
examination and preoperative axillary ultrasound (or nega-
tive cyto-/histopathology). Primary systemic therapy and
primary and secondary breast reconstructions are allowed.
Exclusion criteria include the following: SLNs containing
only isolated tumour cells (<0.2 mm); solitary parasternal
SLN metastasis; bilateral breast cancer; evidence of meta-
static disease; history of invasive breast cancer; previous
treatment of the axilla with surgery or radiation therapy
(except surgery for hidradenitis suppurativa or for other
superficially located skin lesions, such as naevi); pregnancy
or lactation; other prior malignancies, except successfully
treated malignancies that occurred more than five years
before randomization, and except successfully treated basal
cell and squamous cell skin cancer, and carcinoma in situ
of the breast or cervix.
Axillary ultrasound
Axillary ultrasound is standard of care in the Netherlands
for preoperative nodal staging of breast cancer patients
[5]. The following criteria are used during ultrasound
of axillary level 1–3 to identify positive lymph nodes:
long to short axis ratio of <2 (i.e. round), diffuse or
focal cortical thickening, effacement or replacement of
the fatty hilum, and/or nonhilar blood flow (using
Doppler ultrasound, if detectable). As described in the
Dutch breast cancer guideline, cortical thickening of
more than 2.3 mm is considered as the optimal cut-off
point to perform fine-needle aspiration biopsy [5].
Additionally, a subjective assessment of thickening can be
made by the radiologist during real-time imaging, similar
to the studies by Koelliker et al., Abe et al., and Neal et al.
[16, 24, 25]. Fine-needle aspiration biopsy or core biopsy
is recommended when suspicious lymph nodes are identi-
fied. In case of two or more abnormal lymph nodes, the
lymph node with the most suspicious findings is selected
for tissue sampling.
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Sentinel lymph node biopsy
For the SLNB, Technetium-99 m Nanocolloid will be
injected into breast parenchymal tissue surrounding
the tumour, biopsy cavity or periareolar, followed by
lymphoscintigraphic images. The SLN (s) will be iden-
tified during surgery by using the following triple
technique: lymphoscintigraphic images, blue dye and a
gamma probe. Palpation of the axilla after removal of
the SLN (s) is performed to identify and remove suspi-
cious (non-) SLN (s).
As a minimal requirement for pathological assessment,
each SLN is examined at three histological levels (500-μm
intervals). On each level two parallel sections are per-
formed, one for haematoxylin and eosin (H&E) staining
and one for immunohistochemical (IHC) staining. IHC
staining is done only when H&E staining is negative, and
is performed for markers containing at least cytokeratin 8
and 18 (e.g. CAM 5.2, NCL5D3). Lymph nodes submitted
for pathological examination, which are marked by the
surgeon as non-SLNs are examined with H&E and if nega-
tive with cytokeratin IHC staining. The exact diameter of
each metastasis must be determined, as well as describing
the occurrence of extranodal growth. Isolated tumour cells
(<0.2 mm) are considered as SLN negative.
Mastectomy
A mastectomy is defined as the surgical removal of all
glandular breast tissue. The size of the primary tumour is
determined during pathological assessment. The hor-
mone receptor status is determined by IHC staining
and is considered positive if ≥10 % of the cells stain
positive. HER2neu status is determined by IHC and in
case of 2+ determined by CISH or FISH. Histological
tumour grading is assessed according to the modified
Bloom-Richardson grading system. The presence of
multifocality is defined as foci or carcinoma separate from
the primary tumour. The histological tumour type is de-
fined according to the World Health Organization. Pres-
ence of lymphovascular invasion is defined as one or more
tumour cells in a lymphatic or vascular structure.
The modified Bloom-Richardson grading system con-
sists of three components of the tumour morphology
and a score of 1, 2 of 3, is assigned to each of these com-
ponents: the extent of tubule formation (1 = >75 %; 2 =
10–75 %; 3 = <10 %), the nuclear polymorphism (1 =
comparable to normal epithelium; 2 = enlarged, vesicular,
small nucleoli; 3 = polymorphic, vesicular, large nucleoli)
and mitotic activity defined as the number of mitoses
per 2 mm2 (1 = 0–7 mitoses per 2 mm2; 2 = 8–12
mitoses per 2 mm2; 3 = ≥13 mitoses per 2 mm2). The
histological grade is determined by the sum of these
scores, with grade I for the scores 3–5, II for 6–7, and
III for 8–9.
Consent and randomization
Eligible patients will be informed about the study aims,
study procedures, possible adverse events, mechanism of
treatment allocation, and their rights and responsibilities.
After written informed consent is obtained, patients will be
randomized between completion axillary treatment (control
arm) and no completion axillary treatment (study arm).
Stratification factors for randomization include the
following: age (≤50, 50 ≤ 75, >75), oestrogen receptor
status (positive vs. negative), HER2neu status (amplified
vs. not-amplified), lymph node metastasis (micro- vs.
macrometastasis), clinical tumour size prior to any treat-
ment (<3 cm vs. ≥3 cm), grading (grade I-II vs. III -
according to modified Bloom-Richardson grading sys-
tem), primary systemic therapy and participating centre.
Completion axillary treatment
Completion axillary treatment in the control arm can con-
sist of a completion ALND or axillary radiation therapy in
accordance to the Dutch breast cancer guideline [5]. Axil-
lary radiation therapy can either be of axillary level 1 and
2 (i.e. the regions that would be operated upon if an
ALND would be performed), or radiation therapy of axilla
level 1–3 and periclavicular nodes (i.e. conform the re-
gions that were irradiated in the AMAROS trial). Each
participating centre states on beforehand which radiation
strategy they follow for which patient categories.
Radiation therapy
Chest wall irradiation
Radiation therapy of the chest wall after mastectomy is
indicated in specific circumstances depending on the Dutch
and local protocols and therefore not an exclusion criterion
in this study. According to the Dutch breast cancer guide-
line, postoperative radiation therapy after mastectomy can
be considered in patients with 1–3 axillary lymph nodes
containing metastatic disease with at least one risk factor.
Risk factors include angioinvasive growth, grade III tu-
mours, tumour size of ≥3 cm and/or age ≤ 40 years [5]. The
indications for radiation therapy will be clearly defined for
each participating centre to prevent a low-threshold for
chest wall irradiation in study arm B.
Dose and fractionation for chest wall and axilla
A fractionation scheme equivalent to 25 × 2 Gy, 5 fractions
per week is applied; i.e. schemes of 15–16 × 2.66 Gy, 5 frac-
tions per week are allowed as well. In case of an irradical
resection a boost is given to the tumour bed, equivalent to
7–13 × 2 Gy. A simultaneous integrated boost is recom-
mended, with high fraction size not exceeding 2.67 Gy.
Delineation of chest wall and axilla
Delineation of target volumes is performed using the
ESTRO guidelines of Offerson et al. [26]. Delineation of all
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target volumes, including the thoracic wall and heart and
lungs is obligatory. Delineation of other normal structures
is optional. To allow adequate evaluation of the radiation in
the axillary nodal regions, delineation of axillary level 1, 2,
Rotter nodes, 3 and 4 is obligatory, also in case of chest wall
irradiation alone.
Radiation technique and dose distribution
The dose in the Planning Target Volume of the chest wall
with or without axillary and periclavicular nodes must be
between 95–107 % of the prescribed dose. If the distance
between the skin and the pectoral muscle is < 5 mm, it is
allowed to use tissue-equivalent material to increase the
superficial dose. The mean lung dose should be < 5 Gy in
case of tangential fields only, and < 7.5 Gy in case of locore-
gional irradiation. The heart volume receiving > 25 Gy
should be < 20 %; the Mean Heart Dose should preferably
be below 3 Gy, and should certainly not exceed 5 Gy. If
lung or heart constraints cannot be met, some underdose
in the thoracic wall target volume can be accepted to reach
the constraints, provided that the quadrant where the pri-
mary tumour was localized is adequately covered. Respira-
tory control techniques to reduce heart dose are highly
recommended for left sided breast cancer patients. The
dose in the brachial plexus should be kept below an equiva-
lent of 60 Gy in 30 fractions. The minimum, maximum
and mean dose of the axilla level 1, 2, Rotter nodes, 3 and 4
must always be recorded for evaluation purposes, even in
case only chest wall radiation therapy is applied.
Systemic therapy
The indication for systemic therapy is determined for the
individual patient according to the Dutch breast cancer
guideline and multidisciplinary approach. Primary systemic
therapy in clinically T1-2 (pre-systemic therapy) patients is
no exclusion criterion.
Follow-up
During the 10-year follow-up period, outpatient clinic
visits take place annually with physical examination of the
axilla. A mammography is performed annually in the first
five years of follow-up. In year six to ten, a mammography
is performed annually in patients aged ≤60 years or once
every two years in patients aged >60 years. Additional
diagnostic imaging is performed on indication. An axillary
ultrasound is performed in patients with a clinical suspi-
cion of axillary lymph node metastases during follow-up.
If an axillary lymph node metastasis is confirmed by
tissue sampling, staging for distant metastatic disease
is performed in accordance to the Dutch breast cancer
guideline. In patients with a clinical suspicion of dis-
tant metastatic disease during follow-up, staging for
metastatic disease is performed, in combination with
physical examination of the axilla for the detection of
possible axillary lymph node metastases, followed only
by an axillary ultrasound in patients with a clinical
suspicion of axillary lymph node metastases.
Quality of life
Quality of life will be assessed with a set of questionnaires.
The first set is provided pre-randomisation for baseline
measurement, and the following are provided sequentially
post-randomization at 6 months, and at 1, 2, 5 and
10 years. Patients are eligible for evaluation only when at
least the pre-randomisation questionnaire and the subse-
quent questionnaire is completed. The set of question-
naires consist of the EORTC QLQ-C30 and QLQ-BR 23
questionnaire, the Lymph-ICF, STAI-trait and NEO-FFI
questionnaire [27–30]. The combination of these ques-
tionnaires will provide information on the general and
breast cancer specific quality of life, subjective morbidity,
and anxiety and personality traits that might influence the
outcome of quality of life [31].
Adverse events
Adverse events (AEs) are defined as any undesirable ex-
perience occurring to a subject during the study, whether
or not considered related to the protocol treatment. All
AEs reported spontaneously by the subject or observed by
the investigator or his staff will be recorded. Predefined
AEs concerning axillary morbidity include seroma, post-
operative haemorrhage, wound complication/infection,
lymphedema of the arm, lymphedema of the chest wall,
neuralgia, paraesthesia, decreased range of motion of the
arm or shoulder, muscle weakness of the arm or shoulder,
and pain in the arm or shoulder. The severity of the AE is
graded according to the NCI/CTCAE 4.0 grading criteria
into mild, moderate, or severe, in combination with the
degree of limitation in activities of daily living.
A serious adverse event (SAE) is defined as an untoward
medical occurrence or effect related to mastectomy, SLNB,
completion ALND or axillary radiation therapy that results
in death, hospitalisation or prolongation of existing inpa-
tients hospitalisation, or surgery. Other adjuvant treatment
is not considered protocol treatment. The local investigator
of the participating centre where the SAE occurs is respon-
sible to report the SAE to the central data centre within
24 h. The principal investigators of the study are respon-
sible for SAE assessment and reporting to the accredited
medical ethics committee within 15 days. For fatal or life
threatening cases, the term will be maximal 7 days for a
preliminary report with another 8 days for completion of
the report. All SAEs will be followed until they have abated,
or until a stable situation has been reached. Depending on
the event, follow-up may require additional tests or medical
procedures as indicated and/or referral to the general phys-
ician or a medical specialist.
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Statistics
Endpoints
Regional recurrence rate is the primary endpoint in this
study. Secondary endpoints include number of delayed
axillary treatment, distant-disease free survival, overall
survival, local recurrence rate, other-regional recurrence
rate, contralateral breast cancer rate, percentage difference
in the administration of postoperative radiation therapy,
axillary morbidity rate and quality of life. The events
included in the definitions of the different recurrences are
provided in Table 1, and are based on the Maastricht
Delphi Consensus on Event Definition by Moossdorff et
al. [32, 33]. Pathological confirmation of a regional recur-
rence is mandatory, and recommended in case of other sus-
picious lesions. All cases with a lesion that is highly
suspicious for tumour recurrence on imaging, but not ac-
cessible for tissue sampling are presented to the Data Safety
Monitoring Board (DSMB) for an independent review.
Time to event endpoints are defined as the time interval
between the date of randomization and the date of first
suspicion of the predefined recurrence, or the date of death,
whichever comes first, measured in days. Patients in whom
recurrence is not observed and are still alive are censored
at the date of last follow-up. Death from breast cancer and
its treatment, death from a second primary invasive non-
breast cancer, and death from other- or an unknown cause
are recorded.
Administration of postoperative radiation therapy is reg-
istered and the percentage difference between both study
arms is recorded. Axillary morbidity rate will be assessed
using a validated questionnaire and by predefined adverse
events that are recorded by the treating physician. Quality
of life will be assessed using validated questionnaires.
Sample size
Prior data indicate a 5-year regional recurrence free survival
rate of 98 % for the control patient group, and a regional
recurrence free survival rate of 96 % is expected for the
experimental patient group. A difference of no more than
5 % (delta = 5 %) is considered acceptable, when taking in
account the higher morbidity rate caused by completion
axillary treatment in the control arm. The expected regional
recurrence free survival rates and delta result in a sample
size of 399 per arm. Therefore, we will need to study 399
experimental subjects and 399 control subjects to be able
to reject the null hypothesis that the rate for experimental
and control subjects is inferior by at least 5 % with a prob-
ability of 0.8. When taking in account a lost to follow-up
rate of 10 %, 878 patients need to be randomized. An an-
nual accrual of 324 patients can be achieved, based on the
incidence of women diagnosed with invasive breast cancer
in the Netherlands, the rate of patients that is operated on
primarily (excluding patients treated with chemo- or hor-
monal therapy only, or with metastatic disease and frail
elderly), the rate of patients with a positive SLN, treatment
with mastectomy, the 43 participating hospitals, and an
expected accrual rate of 30 %. Therefore, three years will
suffice to include the 878 patients.
Interim analysis
For the interim analysis, the sample size was recalculated
with doubling of the delta from 5 to 10 % to reduce the risk
that the study is incorrectly aborted prematurely. Together
with a lost to follow-up rate of 10 %, the total number of
patients included for this analysis amounts 125.
An independent statistician will perform the interim ana-
lysis after a two-year follow-up of the first 125 included
patients, because the total accrual is expected to complete
within 3 years and because most regional recurrences occur
within two years after initial treatment. According to the
Haybittle-Peto boundary, a P value of 0.001 or less is con-
sidered statistically significant for this analysis [34]. Results
of the interim analysis are reported to the DSMB.
Data safety monitoring board
The independent DSMB comprises a surgeon, medical
oncologist, radiation oncologist and a statistician. The
DSMB will meet annually to discuss the occurrence and
nature of adverse events occurring during the study,
initially at a 1-year interval. During the study, the DSMB
may decide to change the frequency of discussion. All
cases with a lesion that is highly suspicious for tumour
recurrence on imaging, but not accessible for histology
or cytology are presented to the DSMB for an independ-
ent review. Further, the DSMB is informed about the
results of the interim analysis for further interpretation.
DSMB recommendations are sent to the principal inves-
tigators. Should the principle investigators decide not
to fully implement the DSMB recommendations, the
principle investigators will send the recommendation
to the accredited medical ethics committee, including
a note to substantiate why (part of ) this recommenda-
tion will not be followed.
Table 1 Definition of a regional, other-regional, local and dis-
tant recurrence
Classification Events included
Regional
recurrence
Recurrence in an ipsilateral axillary-, infraclavicular-,
or supraclavicular lymph node
Other-regional
recurrence
Recurrence in an ipsilateral internal mammary
lymph node
Local recurrence Recurrence in skin or subcutaneous tissue on the
ipsilateral chest wall
Distant recurrence Recurrence in any other location, including
recurrence involving the
sternal bone, or contralateral lymph nodes
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Stopping rule
The right to discontinue the study prior to inclusion of
the intended number of subjects is reserved to the
principle investigators, but intends only to exercise this
right for valid scientific or administrative reasons such as
a negative advice for continuing the study by the DSMB,
or disappointing accrual so that the total enrolment of
878 patients seems not feasible within the planned study
period.
Final analysis
Primary and secondary endpoints will be analysed per
protocol and in the intention to treat population after
5 and 10 years of follow-up. Primarily, uncorrected chi-
squared statistics will be used to evaluate the null hypoth-
esis. The chi-square test will be based on the Kaplan-Meier
estimator, in case of censored data. Additionally, cox pro-
portional hazards models and Kaplan Meier estimates will
be used to analyse the outcome of both groups and to as-
sess the univariable and multivariable association between
prognostic variables, treatment and events, using the strati-
fication factors. All statistical tests are 1-sided and a P
value of 0.05 or less is considered statistically significant.
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